Back to results
US 11,898,154 B2Granted
Enhanced transgene expression and processing
AssigneeSelexis S.A.
InventorsValerie Le Fourn, Nicolas Mermod, Alexandre Regamey, Montse Buceta, Deborah Ley, Niamh Harraghy, Kaja Kostyrko, Pierre-Alain Giro, David Calabrese
Life of this patent
Estimating the term…
Abstract
Disclosed are constructs and methods for expressing DNAs of interest in particular in non-primate eukaryotic host cells that display advantages with regard quantity and quality of expression including high stability of expression and, if appropriate, transport of the expression product out of the cell.
Claims38
A recombinant nucleic acid molecule that is part of a transposon vector comprising:
- a) a 5′ transposon-specific inverted terminal repeat (ITR) and a 3′ ITR, and
- b) located between the 5′ ITR and the 3′ ITR:
- (i) at least one nucleic acid sequence encoding a transgene expression processing (TEP) protein under the control of a promoter,
- wherein the TEP is selected from the group consisting of human Signal Recognition Particle 14 (hSRP14), human Protein Transport Protein 61α1 (hSec61α1), human Protein Transport Protein 61β (hSec61β), human Protein Transport Protein 61γ (hSec61γ), human Signal Recognition Particle 54 (hSRP54), human Signal Recognition Particle 9 (hSRP9), human Signal Recognition Particle Receptor α (hSRPRα), human Signal Recognition Particle β (hSRPβ), human Calnexin (hCANX), and combinations thereof, and
- (ii) a matrix attachment region (MAR) element,
- wherein the transposon vector increases an expression of a transgene encoding a product of interest in a mammalian cell by at least 10% relative to a plasmid vector comprising the TEP protein.
3 more elements
Dependencies are inferred from the claim text.